CDT Equity (CDT) Competitors

$1.77 -0.09 (-4.84%)

As of 03:16 PM Eastern

CDT vs. ATRA, ATHE, ATNM, ALGS, and ATHA

Should you buy CDT Equity stock or one of its competitors? MarketBeat compares CDT Equity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CDT Equity include Atara Biotherapeutics (ATRA), Alterity Therapeutics (ATHE), Actinium Pharmaceuticals (ATNM), Aligos Therapeutics (ALGS), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry.

How does CDT Equity compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Atara Biotherapeutics has higher revenue and earnings than CDT Equity. CDT Equity is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.70	$32.69M	$3.12	3.00
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

In the previous week, Atara Biotherapeutics had 27 more articles in the media than CDT Equity. MarketBeat recorded 28 mentions for Atara Biotherapeutics and 1 mentions for CDT Equity. CDT Equity's average media sentiment score of 1.89 beat Atara Biotherapeutics' score of 0.17 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
CDT Equity	Very Positive

CDT Equity has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
CDT Equity	N/A	-4,263.33%	-529.91%

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 10.8% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Atara Biotherapeutics has a beta of -0.3, suggesting that its stock price is 130% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

Atara Biotherapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 1.60%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Atara Biotherapeutics is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Atara Biotherapeutics beats CDT Equity on 11 of the 15 factors compared between the two stocks.

How does CDT Equity compare to Alterity Therapeutics?

CDT Equity (NASDAQ:CDT) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Alterity Therapeutics had 1 more articles in the media than CDT Equity. MarketBeat recorded 2 mentions for Alterity Therapeutics and 1 mentions for CDT Equity. CDT Equity's average media sentiment score of 1.89 beat Alterity Therapeutics' score of 0.93 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Very Positive
Alterity Therapeutics	Positive

CDT Equity has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Alterity Therapeutics' return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
Alterity Therapeutics	N/A	N/A	N/A

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 10.8% of CDT Equity shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Alterity Therapeutics beats CDT Equity on 7 of the 10 factors compared between the two stocks.

How does CDT Equity compare to Actinium Pharmaceuticals?

CDT Equity (NASDAQ:CDT) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

CDT Equity has higher earnings, but lower revenue than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
Actinium Pharmaceuticals	$90K	437.51	-$48.82M	-$0.75	N/A

Actinium Pharmaceuticals has a consensus price target of $4.50, suggesting a potential upside of 258.57%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than CDT Equity. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 1 mentions for CDT Equity. CDT Equity's average media sentiment score of 1.89 beat Actinium Pharmaceuticals' score of 1.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Very Positive
Actinium Pharmaceuticals	Positive

CDT Equity has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the broader market.

Actinium Pharmaceuticals' return on equity of -100.85% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 10.8% of CDT Equity shares are held by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Actinium Pharmaceuticals beats CDT Equity on 9 of the 14 factors compared between the two stocks.

How does CDT Equity compare to Aligos Therapeutics?

CDT Equity (NASDAQ:CDT) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 10.8% of CDT Equity shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aligos Therapeutics has higher revenue and earnings than CDT Equity. Aligos Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
Aligos Therapeutics	$2.19M	16.52	-$24.19M	-$8.69	N/A

In the previous week, Aligos Therapeutics had 18 more articles in the media than CDT Equity. MarketBeat recorded 19 mentions for Aligos Therapeutics and 1 mentions for CDT Equity. CDT Equity's average media sentiment score of 1.89 beat Aligos Therapeutics' score of -0.12 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Very Positive
Aligos Therapeutics	Neutral

CDT Equity has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the broader market.

Aligos Therapeutics has a consensus price target of $41.50, suggesting a potential upside of 609.89%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

CDT Equity has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Summary

Aligos Therapeutics beats CDT Equity on 12 of the 16 factors compared between the two stocks.

How does CDT Equity compare to Athira Pharma?

Athira Pharma (NASDAQ:ATHA) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, CDT Equity had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for CDT Equity and 0 mentions for Athira Pharma. CDT Equity's average media sentiment score of 1.89 beat Athira Pharma's score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Athira Pharma	Neutral
CDT Equity	Very Positive

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by insiders. Comparatively, 10.8% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Athira Pharma currently has a consensus price target of $4.00, indicating a potential downside of 63.64%. Given Athira Pharma's higher possible upside, research analysts plainly believe Athira Pharma is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Athira Pharma's return on equity of -107.06% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
CDT Equity	N/A	-4,263.33%	-529.91%

Athira Pharma has a beta of 2.79, meaning that its share price is 179% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

Athira Pharma is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

Summary

Athira Pharma beats CDT Equity on 7 of the 11 factors compared between the two stocks.

Get CDT Equity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDT vs. The Competition

Export

Metric	CDT Equity	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.72M	$2.99B	$6.23B	$12.32B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	0.00	18.04	20.39	25.37
Price / Sales	N/A	259.11	541.93	73.28
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	-0.02	4.31	9.82	6.93
Net Income	-$39.22M	$72.19M	$3.56B	$333.88M
7 Day Performance	-11.94%	-2.34%	0.60%	0.33%
1 Month Performance	-62.10%	-2.62%	-0.70%	2.11%
1 Year Performance	-99.86%	41.07%	36.51%	33.31%

CDT Equity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDT CDT Equity	0.439 of 5 stars	$1.77 -4.8%	N/A	-99.8%	$8.72M	N/A	N/A	3	Gap Up
ATRA Atara Biotherapeutics	1.1639 of 5 stars	$4.76 -2.5%	$6.00 +26.1%	+45.1%	$40.51M	$120.77M	1.53	330	Earnings Report Upcoming Earnings
ATHE Alterity Therapeutics	1.1183 of 5 stars	$4.53 +0.2%	N/A	+13.9%	$40.18M	N/A	N/A	10	Gap Down
ATNM Actinium Pharmaceuticals	3.2383 of 5 stars	$1.26 +5.0%	$4.50 +257.1%	-12.3%	$39.53M	$90K	N/A	30	Positive News Analyst Revision
ALGS Aligos Therapeutics	2.708 of 5 stars	$6.35 -1.4%	$41.50 +553.5%	+20.3%	$39.29M	$2.19M	N/A	90	Trending News Short Interest Increase Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDT) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CDT Equity (CDT) Competitors

CDT vs. ATRA, ATHE, ATNM, ALGS, and ATHA

How does CDT Equity compare to Atara Biotherapeutics?

Summary

How does CDT Equity compare to Alterity Therapeutics?

Summary

How does CDT Equity compare to Actinium Pharmaceuticals?

Summary

How does CDT Equity compare to Aligos Therapeutics?

Summary

How does CDT Equity compare to Athira Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CDT Equity (CDT) Competitors

CDT vs. ATRA, ATHE, ATNM, ALGS, and ATHA

How does CDT Equity compare to Atara Biotherapeutics?

Which has better valuation & earnings, ATRA or CDT?

Does the media favor ATRA or CDT?

Is ATRA or CDT more profitable?

Do insiders and institutionals hold more shares of ATRA or CDT?

Which has more risk and volatility, ATRA or CDT?

Do analysts rate ATRA or CDT?

Summary

How does CDT Equity compare to Alterity Therapeutics?

Which has stronger valuation and earnings, CDT or ATHE?

Do analysts recommend CDT or ATHE?

Does the media favor CDT or ATHE?

Which has more volatility & risk, CDT or ATHE?

Is CDT or ATHE more profitable?

Do institutionals and insiders hold more shares of CDT or ATHE?

Summary

How does CDT Equity compare to Actinium Pharmaceuticals?

Which has stronger valuation and earnings, CDT or ATNM?

Do analysts recommend CDT or ATNM?

Does the media favor CDT or ATNM?

Which has more volatility & risk, CDT or ATNM?

Is CDT or ATNM more profitable?

Do institutionals and insiders hold more shares of CDT or ATNM?

Summary

How does CDT Equity compare to Aligos Therapeutics?

Do insiders & institutionals hold more shares of CDT or ALGS?

Which has higher valuation & earnings, CDT or ALGS?

Does the media refer more to CDT or ALGS?

Which has more risk & volatility, CDT or ALGS?

Do analysts recommend CDT or ALGS?

Is CDT or ALGS more profitable?

Summary

How does CDT Equity compare to Athira Pharma?

Does the media prefer ATHA or CDT?

Do institutionals & insiders hold more shares of ATHA or CDT?

Do analysts rate ATHA or CDT?

Is ATHA or CDT more profitable?

Which has more volatility & risk, ATHA or CDT?

Which has better earnings and valuation, ATHA or CDT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools